• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Curis Inc.

    11/1/24 4:35:37 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email
    SC 13G 1 tm2427347d1_sc13g.htm SCHEDULE 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.   )*

     

    Curis, Inc. 

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share 

    (Title of Class of Securities)

     

    231269309 

    (CUSIP Number)

     

    October 30, 2024 

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

      

     

     

    *       The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

       

     

     

    CUSIP No. 231269309 13G Page 2 of 5 Pages

     

     

    1.NAMES OF REPORTING PERSONS

     

    Thomas A. Satterfield, Jr.

     

    2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      

    (a)¨
    (b)¨

      

    3.SEC USE ONLY

     

    4.CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.SOLE VOTING POWER

     

    137,930

     

    6.SHARED VOTING POWER

     

    552,502

     

    7.SOLE DISPOSITIVE POWER

     

    137,930

     

    8.SHARED DISPOSITIVE POWER

     

    552,502

     

    9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    690,432

     

    10.CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨

     

    11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.05%*

     

    12.TYPE OF REPORTING PERSON

     

    IN

     

     

    *Based on (i) 5,978,945 shares of common stock of the issuer outstanding as of July 25, 2024, as reported by the issuer on its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 and (ii) the issuer’s subsequent sale of 2,398,414 shares of common stock, as reported by the issuer in its Current Report on Form 8-K filed on October 29, 2024. This assumes the exercise of the 198,216 warrants beneficially owned by the Reporting Person.

     

       

     

     

    CUSIP No. 231269309 13G Page 3 of 5 Pages

     

     

    SCHEDULE 13G

    Item 1.

     

    (a)Name of Issuer:

     

    Curis, Inc.

     

    (b)Address of Issuer's Principal Executive Offices:

     

    128 Spring Street

    Building C – Suite 500

    Lexington, MA 02421

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Thomas A. Satterfield, Jr.

     

    (b)Address of Principal Business Office or, if none, Residence:

     

    Thomas A. Satterfield, Jr.

    15 Colley Cove Drive

    Gulf Breeze, Florida 32561

     

    (c)Citizenship:

     

    Incorporated by reference from Item 4 of the Cover Page.

     

    (d)Title of Class of Securities:

     

    Incorporated by reference from the Cover Page.

     

    (e)CUSIP Number:

     

    Incorporated by reference from the Cover Page.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    Incorporated by reference from Item 9 of the Cover Page.

     

    (b)Percent of class:

     

    Incorporated by reference from Item 11 of the Cover Page.

     

       

     

     

    CUSIP No. 231269309 13G Page 4 of 5 Pages

     

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote

     

    Incorporated by reference from Item 5 of the Cover Page.

     

    (ii)Shared power to vote or to direct the vote

     

    Incorporated by reference from Item 6 of the Cover Page.

     

    (iii)Sole power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 7 of the Cover Page.

     

    (iv)Shared power to dispose or to direct the disposition of

     

    Incorporated by reference from Item 8 of the Cover Page.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    With respect to the beneficial ownership report for Thomas A. Satterfield, Jr., 94,465 shares of Common Stock and 59,465 shares of Common Stock issuable upon exercise of Warrants are held by Tomsat Investment & Trading Co., Inc, a corporation wholly owned by Mr. Satterfield and of which he serves as President; 199,286 shares of Common Stock and 79,286 shares of Common Stock issuable upon exercise of Warrants are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 120,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

       

     

     

    CUSIP No. 231269309 13G Page 5 of 5 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      

      November 1, 2024
      Date
       
      /s/ Thomas A. Satterfield, Jr.
      Thomas A. Satterfield, Jr.

      

       

    Get the next $CRIS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Curis Inc.

      SC 13G/A - CURIS INC (0001108205) (Subject)

      11/13/24 2:05:06 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      11/1/24 4:35:37 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      4/15/24 2:12:19 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    See more
    • Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

      LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

      1/3/22 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Appoints John A. Hohneker, M.D. To Board Of Directors

      LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

      12/6/21 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

      1/8/21 4:01:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO Hamdy Ahmed Md

      4 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:26:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Hamdy Ahmed Md

      3 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:24:56 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Duvall Diantha

      4 - CURIS INC (0001108205) (Issuer)

      1/30/25 4:11:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant"). The Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock

      5/6/25 6:16:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Provides First Quarter 2025 Business Update

      Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025. "I am pleased to announce the expansion of the Curis Executive Team with the addition of Dr. Ahmed Hamdy as

      5/6/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Curis with a new price target

      H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

      5/19/25 8:52:11 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Truist initiated coverage on Curis with a new price target

      Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

      11/17/23 7:37:50 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis downgraded by Raymond James

      Raymond James downgraded Curis from Outperform to Mkt Perform

      4/4/22 11:27:43 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Curis Inc.

      10-Q - CURIS INC (0001108205) (Filer)

      5/6/25 8:04:49 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CURIS INC (0001108205) (Filer)

      5/6/25 8:03:06 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Curis Inc.

      DEFA14A - CURIS INC (0001108205) (Filer)

      4/10/25 4:27:59 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Financials

    Live finance-specific insights

    See more
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

      LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

      3/28/25 4:07:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

      LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

      11/7/24 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care